Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew F Shorr

Showing results (91-100 of 322) with videos related to

Pageof 33
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2013
FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trialsKamal M F Itani, Andrew F Shorr
Antibiotics (Basel, Switzerland)|February 27, 2020
Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections-A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence DrugSamareh Azeredo da Silveira, Andrew F Shorr
The Journal of Antimicrobial Chemotherapy|December 15, 2010
Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida kruseiAndrew F Shorr, Chunzhang Wu, Smita Kothari
Pathogens (Basel, Switzerland)|June 26, 2024
Improving Outcomes in Nosocomial Pneumonia: Recent Evidence and More ChallengesIhab H Masri, Bethany Busack, Andrew F Shorr
Current Opinion in Infectious Diseases|October 7, 2022
Novel agents in development for multidrug-resistant Gram-negative infections: potential new options facing multiple challengesRadhika Arya, Breanna S Goldner, Andrew F Shorr
Biomedicines|March 28, 2024
At the Intersection of Critical Care and Infectious Diseases: The Year in ReviewSarah R Sabo, Aarthi Venkatramanan, Andrew F Shorr
Critical Care (London, England)|June 24, 2009
Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulationMarya D Zilberberg, Smita Kothari, Andrew F Shorr
Infection Control and Hospital Epidemiology|June 23, 2009
Cost-effectiveness analysis of a silver-coated endotracheal tube to reduce the incidence of ventilator-associated pneumoniaAndrew F Shorr, Marya D Zilberberg, Marin Kollef
Chest|May 11, 2020
Bang for Your Buck: Could Medicare's Hospital Value-Based Purchasing Program Rein in Health-Care Spending in Pneumonia?Marya D Zilberberg, Jennifer Tjia, Andrew F Shorr
The Journal of Antimicrobial Chemotherapy|October 1, 2005
Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studiesAndrew F Shorr, Mark J Kunkel, Marin Kollef
Pageof 33

Showing results (91-100 of 322) with videos related to

Sort By:
Pageof 33
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2013
FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trialsKamal M F Itani, Andrew F Shorr
Antibiotics (Basel, Switzerland)|February 27, 2020
Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections-A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence DrugSamareh Azeredo da Silveira, Andrew F Shorr
The Journal of Antimicrobial Chemotherapy|December 15, 2010
Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida kruseiAndrew F Shorr, Chunzhang Wu, Smita Kothari
Pathogens (Basel, Switzerland)|June 26, 2024
Improving Outcomes in Nosocomial Pneumonia: Recent Evidence and More ChallengesIhab H Masri, Bethany Busack, Andrew F Shorr
Current Opinion in Infectious Diseases|October 7, 2022
Novel agents in development for multidrug-resistant Gram-negative infections: potential new options facing multiple challengesRadhika Arya, Breanna S Goldner, Andrew F Shorr
Biomedicines|March 28, 2024
At the Intersection of Critical Care and Infectious Diseases: The Year in ReviewSarah R Sabo, Aarthi Venkatramanan, Andrew F Shorr
Critical Care (London, England)|June 24, 2009
Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulationMarya D Zilberberg, Smita Kothari, Andrew F Shorr
Infection Control and Hospital Epidemiology|June 23, 2009
Cost-effectiveness analysis of a silver-coated endotracheal tube to reduce the incidence of ventilator-associated pneumoniaAndrew F Shorr, Marya D Zilberberg, Marin Kollef
Chest|May 11, 2020
Bang for Your Buck: Could Medicare's Hospital Value-Based Purchasing Program Rein in Health-Care Spending in Pneumonia?Marya D Zilberberg, Jennifer Tjia, Andrew F Shorr
The Journal of Antimicrobial Chemotherapy|October 1, 2005
Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studiesAndrew F Shorr, Mark J Kunkel, Marin Kollef
Pageof 33